XEN-D0501, a Novel Transient Receptor Potential Vanilloid 1 Antagonist, Does Not Reduce Cough in Patients with Refractory Cough.

Maria G Belvisi Mark A Birrell Michael A WortleySarah A MaherImran SatiaHuda BadriKimberley HoltPatrick RoundLorcan McGarveyJohn FordJaclyn Ann Smith

Published in: American journal of respiratory and critical care medicine (2017)

XEN-D0501 demonstrated superior efficacy and potency in preclinical and clinical capsaicin challenge studies; despite this improved pharmacodynamic profile, spontaneous cough frequency did not improve, ruling out TRPV1 as an effective therapeutic target for refractory cough. Clinical trial registered with www.clinicaltrialsregister.eu (2014-000306-36).

Keyphrases

clinical trial
open label
cell therapy
risk assessment
spinal cord
cerebral ischemia
case control